Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) announced inducement equity grants on March 16, 2026 to newly hired employees: 235,700 stock options and 33,450 RSUs. Options carry a 10-year term and an exercise price of $23.23, equal to the closing price on the grant date.

Options vest over four years (25% at one year, then 36 monthly installments). RSUs vest in four equal annual installments on March 15, 2027–2030 and are subject to continued service and the 2026 Inducement Plan.

News Market Reaction – ZBIO

+1.08%

10 alerts

+1.08% News Effect

-5.7% Trough in 3 min

+$13M Valuation Impact

$1.22B Market Cap

0.1x Rel. Volume

On the day this news was published, ZBIO gained 1.08%, reflecting a mild positive market reaction. Argus tracked a trough of -5.7% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $1.22B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement stock options: 235,700 shares Inducement RSUs: 33,450 RSUs Option exercise price: $23.23 per share +5 more

8 metrics

Inducement stock options 235,700 shares Non-qualified stock options granted to new hires on Mar 16, 2026

Inducement RSUs 33,450 RSUs Restricted stock units granted to new hires on Mar 16, 2026

Option exercise price $23.23 per share Equal to Zenas’ closing stock price on the grant date

Option term 10 years Non-qualified stock options granted under 2026 Inducement Plan

Initial option vesting 25% after 1 year First tranche vests on one-year work anniversary

Remaining option vesting 36 monthly installments Remaining options vest monthly over the next three years

RSU vesting schedule 4 equal installments Annual vesting on Mar 15 from 2027 through 2030

ATM program size $200,000,000 At-the-market common stock sales capacity under S-3ASR shelf

Market Reality Check

Price: $22.30 Vol: Volume 600,540 vs 20-day ...

normal vol

$22.30 Last Close

Volume Volume 600,540 vs 20-day average 566,832, indicating slightly elevated trading activity. normal

Technical Price 23.23 is trading above the 200-day MA at 22.53 despite a -3.37% move over 24 hours.

Peers on Argus

ZBIO fell -3.37% while peers showed mixed moves: declines in AVXL and SANA, gain...

ZBIO fell -3.37% while peers showed mixed moves: declines in AVXL and SANA, gains in GERN, PRAX, and QURE. This pattern points to company-specific trading rather than a uniform biotech sector move.

Historical Context

5 past events · Latest: Mar 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	Earnings report	Neutral	-2.1%	Fourth quarter and full-year 2025 results with pipeline and financing update.
Feb 20	Inducement grants	Neutral	+1.0%	Inducement stock options and RSUs granted to new hires under 2026 plan.
Feb 09	Clinical data update	Positive	+3.1%	Phase 2 MoonStone trial showed strong obexelimab efficacy in RMS.
Feb 04	Conference appearance	Neutral	+4.8%	Announcement of presentation at Guggenheim Emerging Outlook: Biotech Summit 2026.
Jan 16	Inducement grant	Neutral	+3.6%	Single large inducement stock option grant to a newly hired employee.

Pattern Detected

Recent news — including clinical updates, conferences, and prior inducement grants — has generally seen price moves that align directionally with the tone of each announcement, with no strong pattern of consistent selloffs on positive news.

Recent Company History

Over the last few months, Zenas has reported key milestones, including positive Phase 2 MoonStone data for obexelimab in relapsing multiple sclerosis and participation in a Guggenheim biotech summit. It has also frequently used inducement equity grants to hire talent. An earnings and corporate update on Mar 16, 2026 highlighted pipeline progress and financing. Today’s inducement grants continue the pattern of using equity-based compensation alongside broader clinical and corporate developments.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2025-10-08

$200,000,000 registered capacity

An effective S-3ASR shelf filed on 2025-10-08 allows Zenas to offer a mix of securities, including an at-the-market program for up to $200,000,000 of common stock through Jefferies. The shelf has been used at least once via a 424B7 filing on 2026-01-28, which permitted resale of 8,533 existing shares.

Market Pulse Summary

This announcement described routine inducement equity awards — 235,700 stock options and 33,450 RSUs...

Analysis

This announcement described routine inducement equity awards — 235,700 stock options and 33,450 RSUs at an exercise price of $23.23 — granted to new hires under Nasdaq Listing Rule 5635(c)(4). It continues Zenas’ use of its 2026 Inducement Plan to attract talent while advancing its autoimmune pipeline. Investors may track the pace of such grants alongside existing capital-raising capacity under the S-3ASR shelf and broader clinical and financial updates from the company.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units, exercise price, +3 more

7 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 235,700 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"an aggregate of 33,450 restricted stock units of the Company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"an exercise price per share of $23.23, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The Stock Options will vest over a four-year period, with 25% of the shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

inducement grant financial

"as the “Inducement Grant”). The Stock Options have a ten-year term"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

inducement plan financial

"subject to, the terms and conditions of the Company’s 2026 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on March 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 235,700 shares of the Company’s common stock (“Stock Options”) and an aggregate of 33,450 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The Stock Options have a ten-year term and an exercise price per share of $23.23, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Stock Options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each of the employees’ first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments. The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of March 15, 2027, March 15, 2028 March 15, 2029 and March 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Investor and Media Contact:

Argot Partners
Zenas@argotpartners.com

FAQ

What equity inducement did Zenas BioPharma (ZBIO) announce on March 16, 2026?

Zenas granted 235,700 stock options and 33,450 RSUs to new hires on March 16, 2026. According to the company, the awards were made as inducements under Nasdaq Rule 5635(c)(4) and are subject to the 2026 Inducement Plan.

What is the exercise price and term for the ZBIO stock options granted March 16, 2026?

The stock options have a $23.23 exercise price and a 10-year term. According to the company, $23.23 equals ZBIO's closing price on the grant date and the options expire ten years after grant.

How do the ZBIO options vest for employees hired under the March 16, 2026 inducement grants?

The options vest over four years: 25% after one year, then monthly over the next 36 months. According to the company, vesting is conditioned on continued service through each vesting date.

What is the vesting schedule for the ZBIO restricted stock units (RSUs) granted March 16, 2026?

The RSUs vest in four equal annual installments on March 15, 2027, 2028, 2029, and 2030. According to the company, vesting is subject to continued service and the terms of the 2026 Inducement Plan.

Are the March 16, 2026 ZBIO inducement grants subject to any plan or service conditions?

Yes. The awards are governed by the 2026 Inducement Plan and require continued service to vest. According to the company, each award is also subject to the applicable award agreement terms and vesting conditions.